4Kaplan JE;Hanson DL;Navin TR.Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States:reassessment of indications for chemoprophylaxis[J],1998(04).
5Phair JP;Munoz A;Detels R.The risk of Pneumocystis carinii pneumonia among men with human immunodeficiency virus type 1[J],1990(22).
2Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
3Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
4Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
5Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
6Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
7Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.
